Business

 


PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022

Global hemophilia market driven by the uptake of premium priced, long-acting recombinant treatments


Companies & Markets

© companiesandmarkets.com
28.07.2014 21:19:01 - PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - a new market research report on companiesandmarkets.com

(live-PR.com) - Emerging Therapies to Seize Half of Hemophilia Market Share by 2018, Changing Landscape. The recombinant hemophilia market is set to change drastically over the next four years, with emerging long-acting treatments expected to take over half of the marketplace and significant growth forecast for China.

The hemophilia market expansion in seven major countries – the US, France, Germany, Italy, Spain, UK

 

and Japan – will be driven by the uptake of premium-priced, long-acting recombinant treatments, beginning in the US in 2014 and the five European countries (5EU) in 2015.

The US is expected to show the fastest uptake of these therapies, which will capture 50% of the country´s total hemophilia market within the three years following their launch. Meanwhile, growth in the 5EU is anticipated to be slightly slower, with new products gaining a 50% share approximately four years after launch.

The current prophylaxis treatment schedule requires patients to infuse the product twice to three times weekly. Patients and physicians are now eager to adopt long-acting therapies to alleviate this treatment burden; however, the high annual cost of therapy remains a point of concern among physicians in the 5EU.

While premium pricing opportunities exist for long-acting products, GlobalData suggests that companies hoping to penetrate these markets will not be best served by over-reaching for significant price increases above the established therapies.

Analysts believe that premium pricing opportunities are greater for recombinant FIX products, which offer a significant improvement in patients´ treatment schedules. Meanwhile, the ability of recombinant FVIII products to command increased prices over Advate or Recombinate will likely be limited due to modest potential reduction in weekly infusions.

The developing countries of China and Argentina are anticipated to undergo significant hemophilia market growth by 2022, driven by increased rates of diagnosis and greater adoption of recombinant regimens.

Premium pricing opportunities for new products in these countries will still be restricted by the economic barriers that have traditionally prevented recombinant therapies from capturing substantial shares in these markets.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-an ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-an ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-an ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Re ..

About Us
Companiesandmarkets.com aims to provide clients with the widest array of reports and market research across all of our 27 industry sectors. Companiesandmarkets.com’s team of analysts are available to offer clients specific advice on finding relevant information and also purchasing the correct market research reports for their specific business needs. Over 100,000 companies are listed in Companiesandmarkets.com´s online reports database, providing clients with an extensive coverage not only of company profiles but also of high value and insightful market reports.


Author:
Mike King
e-mail
Phone: 44 0203 086 8600


 

Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact Live-PR.com. We are not able to assist you. Live-PR.com disclaims content contained in this article. Live-PR.com is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article